UNSPSC 51434952: Methyclothiazide/pargyline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434952 Methyclothiazide/pargyline is a Commodity code identifying a specific pharmaceutical product, but state and local procurement activity under this code shows minimal direct relevance to the listed medication. The City of Tampa's Fire Rescue solicitation tagged to this code (Bid No. 26-P-00188, posted April 24, 2026) actually procures a broad range of Advanced Life Support medications—Labetalol HCI, Epinephrine, Adenosine, and Diltiazem—none of which is the methyclothiazide/pargyline compound the code nominally identifies. This mismatch suggests either a cataloging error in the source data or a state and local procurement office applying the code to a broader medication family than its UNSPSC definition intends. Based on the single visible opportunity, the code shows little decision-relevant recent activity tied to its stated commodity.

The City of Tampa Purchasing Department's April 2026 IFB represents the only recent state and local solicitation identified under this code. The opportunity calls for 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem, with a firm nine-month minimum shelf life at delivery, delivery within ten calendar days, and a contract value of $40,000 covering one year from award with two optional one-year renewals and up to three additional 30-day extensions. The City applied a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation, capped at $10,000, and required OSHA-compliant Safety Data Sheets and WCAG 2.2 Level AA accessibility documentation for all submissions. Electronic bids closed April 8, 2026, through the OpenGov eProcurement Portal. The narrow scope of recent opportunities and the apparent mismatch between the code definition and actual procurement content suggest this code merits watch status rather than active pursuit unless additional state or local opportunities emerge that align more clearly with the methyclothiazide/pargyline specification.